Dergiler / Medicine Science / 2019 / Cilt: 8 - Sayı: 3

Na+ channel blocker enhances metformin effects on neuroblastoma cell line

Sayfa
636–640
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

According to our result, valproic acid increased metformin antitumor effects more than metformin alone

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:The aim of the current study is the evaluation of valproic acid and Metformin antitumor effect on neuroblastoma (SH-SY5Y) and answer the question, is valproic acid (VPA) increase Metformin (MET) antitumor effect on the SH-SY5Y cancer cell line or not.
📊
Temel Bulgular & Veri:The SH-SY5Y cell line was grown in culture medium.
💡
Sonuç & Katkı:According to our result, valproic acid increased metformin antitumor effects more than metformin alone
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

The aim of the current study is the evaluation of valproic acid and Metformin antitumor effect on neuroblastoma (SH-SY5Y) and answer the question, is valproic acid (VPA) increase Metformin (MET) antitumor effect on the SH-SY5Y cancer cell line or not. The SH-SY5Y cell line was grown in culture medium. A different dose of MET and VPA were applied to SH-SY5Y cancer cell lines for 24 hrs. 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide (MTT) cell viability, Annexin-V-FITC apoptosis, Total Antioxidant Capacity (TAC) and Total Oxidant Status (TOS) tests were done 24 hours after drug administration. As a result of the tests, the combination of MET and VPA reduced cancer cell viability compared with the control group (p<0.001). According to our result, valproic acid increased metformin antitumor effects more than metformin alone

🔖

Bu Makaleye Atıf Yap

TAGHİZADEHGHALEHJOUGHİ, A., HACİMUFTUOGLU, A., YİLMAZ, A. (2019). Na+ channel blocker enhances metformin effects on neuroblastoma cell line. Medicine Science, Cilt: 8 - Sayı: 3, 636–640. https://ajindex.com/articles/276985

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Davidoff, AM. Neuroblastoma. Semin Pediatr Surg, 2012;21:2-14
  2. Young JL Jr, Ries LG, Silverberg E, et al. Cancer incidence, survival, and mortality for children younger than age 15 years. Cancer. 1986;58:598-602
  3. Kumar A, Al-Sammarraie N, DiPette DJ, et al. Metformin impairs Rho GTPase signaling to induce apoptosis in neuroblastoma cells and inhibits growth of tumors in the xenograft mouse model of neuroblastoma. Oncotarget, 2014;5:11709-22
  4. Shabbeer S, Kortenhorst MS, Kachhap S, et al. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate. 2007;67:1099-10
  5. Xia Q, Sung J, Chowdhury W, et al. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res. 2006:66:7237-44
  6. Sidana A, Wang M, Chowdhury WH, et al. Does valproic acid induce neuroendocrine differentiation in prostate cancer? J Biomed Biotechnol. 2011;2011:607480
  7. Farber NB, Jiang XP, Heinkel C, et al. Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. Mol Psychiatry, 2002;7:726-33
  8. Kang H, Gillespie TW, Goodman M, et al. Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer. Cancer, 2014;120:1394-400
  9. Sidana A, Wang M, Shabbeer S, et al., Mechanism of growth inhibition of prostate cancer xenografts by valproic acid. J Biomed Biotechnol, 2012;2012:180363
  10. Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E, et al. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int, 2006;6:2
  11. Kim MS, Blake M, Baek JH, et al., Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 2003;63:7291-300
  12. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, et al, Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther. 2010;9:1092-9
  13. Evans JM, Le Marchand-Brustel Y, Tanti JF, et al, Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304-5
  14. Zhang ZJ, Bi Y, Li S, et al, Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis. Am J Epidemiol, 2014;180:11-4
  15. Lau YK, Du X, Rayannavar V, et al. Metformin and erlotinib synergize to inhibit basal breast ca